Biodesix is a clinical diagnostics company that develops innovative, blood-based tests—using proteomics and advanced analytics—to help diagnose and manage lung diseases, including lung cancer, ultimately supporting more personalized treatment decisions.
They are currently trading at all time low. They have an active LinkedIn showing lots of open engineering roles.
Insider holding is currently around 25% so they are holding strong after the plunge from $1 to $0.6 per share